WILMINGTON, MASSACHUSETTS--(Marketwire - May 16, 2008) - DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, today announced the filing of a shelf registration statement with the Securities and Exchange Commission. After the shelf registration statement has become effective, DUSA may, from time-to-time, offer its common stock, preferred stock, debt securities, depository shares and warrants up to an aggregate public offering price of up to $75 million. These securities may be offered, separately or together, in separate series, in amounts, at prices and on terms to be set forth in a filing with the Securities and Exchange Commission at the time of such offering.
